Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter D. Davis is active.

Publication


Featured researches published by Peter D. Davis.


FEBS Letters | 1991

A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli

Robert E. Muid; M.Maureen Dale; Peter D. Davis; Lucy H. Elliott; Christopher Huw Hill; Hari Kumar; Geoffrey Lawton; Breda M. Twomey; J. Wadsworth; Sandra E. Wilkinson; John S. Nixon

A novel, bis‐indolylmaleimide, Ro 31‐8425, bearing a conformationally restricted side chain, inhibits protein kinase C isolated from rat brain and human neutrophils with a high degree of selectivity over cAMP‐dependent kinase and Ca2−/calmodulin‐dependent kinase. It also inhibits phorbol ester‐induced intracellular events known to be mediated by protein kinase C(p47 phosphorylation in intact platelets, CD3 and CD4 down‐regulation in T‐cells). Ro 31‐8425 inhibited superoxide generation in human neutrophils activated by both receptor stimuli (formyl‐methionyl‐leucylphenylalanine, opsonized zymosan. IgG and heat aggregated IgG) and post‐rcceptor stimuli (1,2‐dioctanoylglycerol and fluoride). The compound also blocked antigen driven, but not IL‐2 induced, T‐cell proliferation. These results support a central role for protein kinase C in the activation of the respiratory burst and antigen‐driven T‐cell proliferation.


Inflammation Research | 1991

Modulation of cellular processes by H7, a non-selective inhibitor of protein kinases.

John S. Nixon; Sandra E. Wilkinson; Peter D. Davis; A. D. Sedgwick; J. Wadsworth; D. Westmacott

H7 has been described as a potent inhibitor of protein kinase C (PKC) and has been widely used to investigate the regulatory role of this enzyme in intact cell systems. In this comparative study between H7 and the microbial alkaloid, staurosporine, we found that the former inhibited rat brain PKC and cAMP dependent protein kinase with IC50 values of 18 and 16 μM respectively whereas the latter was a much more potent inhibitor of both kinases with IC50 values of 9.5 nM and 42 nM respectively. H7, at concentrations up to 100 μM, failed to block cellular events induced by phorbol esters, agents which specifically stimulate PKC, yet was a potent inhibitor of IL-2 induced T cell proliferation with an IC50 value of 19 μM. In contrast, staurosporine was a potent inhibitor of both phorbol ester induced p47 phosphorylation in platelet (I50 value=540 nM) and also CD3 and CD4 down-regulation in T cells (I50 values 200 nM and 50 nM respectively). Staurosporine was also a potent inhibitor of IL-2 induced T cell proliferation I50 value=9 nM). These results provide a strong argument against the use of H7 to probe for PKC involvement in cellular processes.


Tetrahedron Letters | 1990

A convenient synthesis of bisindolyl- and indolylaryl-maleic anhydrides

Peter D. Davis; Rino A. Bit; Stephen A. Hurst

Abstract The reaction of indolyl-3-glyoxylyl chlorides, easily prepared from the corresponding indoles, with arylacetic acids provides indolylaryl maleic anhydrides including bisindolyl rnaleic anhydrides.


Inflammation Research | 1992

Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor

M. J. Mulqueen; D. Bradshaw; Peter D. Davis; L. Elliott; T. A. Griffiths; Christopher Huw Hill; Hari Kumar; Geoffrey Lawton; John S. Nixon; A. D. Sedgwick; J. Wadsworth; D. Westmacott; Sandra E. Wilkinson

The protein kinase C family of enzymes is thought to be important in mediating signal transduction. Ro 31-8830 is a novel, potent inhibitor of protein kinase C, derived from the non-selective protein kinase inhibitor staurosporine. In this paper we demonstrate the selectivity of Ro 31-8830 for protein kinase C over other protein kinases and its ability to inhibit protein kinase-C-mediated events in platelets and lymphocytes. In addition, we describe a novel system for thein vivo evaluation of inhibitors of protein kinase C, and we demonstrate the oral anti-inflammatory activity of Ro 31-8830. This finding has implications for the treatment of inflammatory disorders in the clinic.


Inflammation Research | 1986

The inhibitory profiles of hog pancreatic and human rheumatoid synovial cell phospholipases A2

John S. Nixon; Sandra E. Wilkinson; Peter D. Davis; David P. Bloxham

ConclusionsThe protective effect of Harmons and Rosenthals agents, and of the Upjohn inhibitors [4] is most simply ascribed to their shielding of His-48 by reversible binding at the enzymes active site. However, protection by an allosteric mechanism cannot be excluded for any of these compounds. The lack of protection shown by other reversible inhibitors suggests that these agents do not bind to the enzyme active site. Some of these agents e.g. mepacrine, may inhibit PLA2 by interacting with its membrane substrate, so perturbing its architecture and electrostatic properties, and thus interfering with enzyme approach and/or penetration [5]. Further information on enzyme-inhibitor interactions may be derived from n.m.r. studies.A crude extract of HRS enzyme was used in this study. Nevertheless, it seems that this enzyme is similar in many respects to hog pancreatic PLA2. In particular, the similar protection profiles and pH dependencies of pBPB inactivation suggest that the pBPB modification site is the same for both enzymes. Also, the lack of preferential inhibition of either enzyme by active-site directed inhibitors suggests a degree of similarity in the architecture of their catalytic centres; however, studies with more potent inhibitors may uncover differences here.


Biochimica et Biophysica Acta | 1989

1H-NMR and protection studies of interactions between ligands and bovine pancreatic phospholipase A2

Michael P. Williamson; Peter D. Davis; Michael John Broadhurst; John S. Nixon

A number of long-chain amines and naphthylamine sulfonates have been studied for their ability to inhibit bovine pancreatic phospholipase A2 (PLA2) and to protect PLA2 against alkylation of the active site histidine by p-bromophenacyl bromide. Their areas of interaction on the enzyme were further delineated using observations of chemical shift changes of assigned aromatic signals in the 1H-NMR spectrum of PLA2, while the bound conformations of two amine inhibitors were revealed using transferred nuclear Overhauser effects. The alkyl amines bind rather non-specifically on the surface of the enzyme, over the active site cleft and the interface recognition site.


Journal of Medicinal Chemistry | 1992

Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity

Peter D. Davis; Lucy H. Elliott; William Harris; Christopher Huw Hill; Steven A. Hurst; Elizabeth Keech; M. K. Hari Kumar; Geoffrey Lawton; John S. Nixon; Sandra E. Wilkinson


Journal of Medicinal Chemistry | 1992

Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides

Peter D. Davis; Christopher Huw Hill; Geoffrey Lawton; John S. Nixon; Sandra E. Wilkinson; Steven A. Hurst; Elizabeth Keech; Susan E. Turner


Journal of Medicinal Chemistry | 1993

Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction

Rino A. Bit; Peter D. Davis; Lucy H. Elliott; William Harris; Christopher Huw Hill; Elizabeth Keech; Hari Kumar; Geoffrey Lawton; Anna Maw; John S. Nixon; David Vesey; Julie Wadsworth; Sandra E. Wilkinson


Archive | 1995

4- 3-indolyl!-1H-pyrrolone

Peter D. Davis; Christopher Huw Hill; Geoffrey Lawton

Collaboration


Dive into the Peter D. Davis's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Geoffrey Lawton

University of Hertfordshire

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Geoffrey Lawton

University of Hertfordshire

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge